IPO Year: 2026
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2026 | Overweight | Cantor Fitzgerald | |
| 3/2/2026 | $32.00 | Overweight | Morgan Stanley |
| 3/2/2026 | $29.00 | Overweight | Analyst |
| 3/2/2026 | $26.00 | Outperform | Mizuho |
| 3/2/2026 | $34.00 | Buy | BofA Securities |
| 2/26/2026 | $7.00 | Underperform | Wedbush |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Cantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight
Morgan Stanley initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $32.00
Analyst initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $29.00
Mizuho initiated coverage of Eikon Therapeutics with a rating of Outperform and set a new price target of $26.00
BofA Securities initiated coverage of Eikon Therapeutics with a rating of Buy and set a new price target of $34.00
Wedbush initiated coverage of Eikon Therapeutics with a rating of Underperform and set a new price target of $7.00
8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
10-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)
SCHEDULE 13D - Eikon Therapeutics, Inc. (0001861123) (Subject)
SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)
S-8 - Eikon Therapeutics, Inc. (0001861123) (Filer)
8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
Fastest customizable press release news feed in the world
Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates. "2025 was an important year of progress for Eikon's business and clinical programs," said Roger M. Perlmutter, M.D., Ph.D., Chief Execut
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)